Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000000654 | SCV004222617 | pathogenic | Phenylketonuria | 2023-12-30 | reviewed by expert panel | curation | The c.1066-3C>T variant in PAH has been reported in multiple individuals with Classic PKU and MHP (BH4 deficiency excluded). (PMID: 9634518, 27121329). It has been detected with multiple pathogenic variants: c.1222C>T (p.Arg408Trp) (in trans, PMID: 27121329); c.1315+1G>A (PMID: 17502162); p.G272X, p.S310F (PMID: 23430918); c.194T>C (p.I65T), c.1208C>T (p.A403V), c.398_401del (p.N133fs), c.1222C>T (p.R408W) 2 patients, c.165delT (p.F55fs), c.168+5G>C (IVS2+5G>C) (PMID: 22526846). This variant has an extremely low allele frequency in ExAC and gnomAD (MAF=0.00014). This variant has 0% enzyme activity. This variant resulted in the skipping of exon 11 with the premature termination of RNA translation downstream from exon 12 (PMID: 8098245). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_very-strong, PP4_Moderate, PM2_supporting. |
Counsyl | RCV000000654 | SCV000220862 | likely pathogenic | Phenylketonuria | 2014-11-06 | criteria provided, single submitter | literature only | |
Eurofins Ntd Llc |
RCV000088742 | SCV000225209 | pathogenic | not provided | 2014-11-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000000654 | SCV000836557 | pathogenic | Phenylketonuria | 2024-10-22 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 10 of the PAH gene. It does not directly change the encoded amino acid sequence of the PAH protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs62507344, gnomAD 0.02%). This variant has been observed in individual(s) with mild hyperphenylalaninemia and phenylketonuria (PMID: 8098245, 17502162, 19444284, 22526846, 22698810, 23357515, 24368688, 26666653). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 623). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 8098245, 22698810). For these reasons, this variant has been classified as Pathogenic. |
Illumina Laboratory Services, |
RCV000000654 | SCV000914555 | pathogenic | Phenylketonuria | 2018-12-18 | criteria provided, single submitter | clinical testing | Across a selection of the available literature, the PAH c.1066-3C>T splice region variant has been reported in at least six studies in which it is found in a total of 15 probands including one in a homozygous state and 14 in a compound heterozygous state (Abadie et al. 1993; Dobrowolski et al. 2009; Heintz et al. 2012; Sterl et al. 2013; Ho et al. 2014; Jeannesson-Thivisol et al. 2015). Control data are unavailable for this variant, which is reported at a frequency of 0.00019 in the European (Finnish) population of the Genome Aggregation Database. Liver biopsy from a compound heterozygous proband found 1.5% of normal PAH activity (Abadie et al. 1993). RT-PCR of proband derived lymphoblast cells indicated exon 11 skipping and COS-1 cells transfected with minigenes confirmed c.1066-3C>T as the cause of exon 11 skipping (Heintz et al. 2012). Based on the evidence, the c.1066-3C>T variant is classified as pathogenic for phenylalanine hydroxylase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000000654 | SCV001362284 | pathogenic | Phenylketonuria | 2019-05-13 | criteria provided, single submitter | clinical testing | Variant summary: PAH c.1066-3C>T alters a conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Two predict the variant abolishes a 3' acceptor site and two predict the variant weakens a 3' acceptor site. At least one publication reports experimental evidence that this variant affects mRNA splicing leading to exon 11 skipping (Heintz_2012). The variant allele was found at a frequency of 4e-05 in 250904 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in PAH causing Phenylalanine Hydroxylase Deficiency (Phenylketonuria) (4e-05 vs 0.0079), allowing no conclusion about variant significance. c.1066-3C>T has been reported in the literature in multiple individuals affected with Phenylketonuria and Hyperphenylalaninemia (Heintz_2012, Reblova_2013, Sterl_2013). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Gene |
RCV000088742 | SCV001822273 | pathogenic | not provided | 2020-01-06 | criteria provided, single submitter | clinical testing | Published in vitro study demonstrates the c.1066-3C>T variant results in skipping of exon 11 (Abadie et al., 1993); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Responsiveness to tetrahydrobiopterin (BH4) therapy is not clear (Sarkissian et al., 2012); This variant is associated with the following publications: (PMID: 33101986, 32668217, 31589614, 22526846, 8098245, 29288420, 26666653, 24368688, 7657610, 15464430, 22513348, 21147011, 22698810, 22841515, 23430918, 23672685) |
Baylor Genetics | RCV000000654 | SCV004201381 | pathogenic | Phenylketonuria | 2024-03-30 | criteria provided, single submitter | clinical testing | |
Laboratory of Medical Genetics, |
RCV000000654 | SCV005051907 | pathogenic | Phenylketonuria | 2024-02-01 | criteria provided, single submitter | curation | |
Mayo Clinic Laboratories, |
RCV000088742 | SCV005414104 | pathogenic | not provided | 2024-09-03 | criteria provided, single submitter | clinical testing | PP4_moderate, PM2, PM3_very_strong |
OMIM | RCV000000654 | SCV000020804 | pathogenic | Phenylketonuria | 1993-01-01 | no assertion criteria provided | literature only | |
De |
RCV000088742 | SCV000119325 | not provided | not provided | no assertion provided | not provided | ||
Natera, |
RCV000000654 | SCV002088631 | pathogenic | Phenylketonuria | 2021-02-19 | no assertion criteria provided | clinical testing |